Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers

被引:33
|
作者
Nobashi, Tomomi W. [1 ]
Nishimoto, Yuko [1 ]
Kawata, Yujiro [1 ]
Yutani, Hidetaka [1 ]
Nakamura, Masaki [1 ]
Tsuji, Yuichi [1 ]
Yoshida, Atsushi [1 ]
Sugimoto, Akihiko [1 ]
Yamamoto, Takayuki [1 ]
Alam, Israt S. [2 ]
Noma, Satoshi [1 ]
机构
[1] Tenri Hosp, Dept Radiol, Nara, Japan
[2] Stanford Univ, Sch Med, Dept Radiol, Mol Imaging Program Stanford MIPS, Stanford, CA USA
来源
BRITISH JOURNAL OF RADIOLOGY | 2020年 / 93卷 / 1115期
关键词
ADVERSE EVENTS; POOLED ANALYSIS; DEATH; NIVOLUMAB; THERAPY; KL-6; IPILIMUMAB; BLOCKADE; SMOKING; RISK;
D O I
10.1259/bjr.20200409
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: To investigate the clinical and radiological features of immune checkpoint inhibitor-related pneumonitis (ICI-P), a rare but serious pulmonary complication of cancer immunotherapy and to evaluate key differences between lung cancer (LC) and non-LC patients. Methods: 247 patients (LC, n = 151) treated with ICI for malignancies were retrospectively screened in a single institute. The number of patients, history of other immune-related adverse events (irAE), the onset, serum KL-6 levels, and chest CT features (types of pneumonitis, symmetry, laterality, location) were recorded for the ICI-P population and compared for LC and non-LC groups. Results: ICI-P was identified in 26 patients in total (LC, n = 19; non-LC, n = 7). The incidence of other irAE was significantly higher in ICI-P group (63%) compared with patients without ICI-P (34%) (p = 0.0056). An earlier onset of ICI-P was recorded in LC (78 days) compared to non-LC patients (186 days) (p = 0.0034). Serum KL-6 was significantly elevated only in the non-LC group when ICI-P was noticed (p = 0.029). Major CT findings of ICI-P, irrespective of primary disease, were organizing pneumonia pattern and ground glass opacities. LC patients commonly exhibited consolidation and traction bronchiectasis and were prone to asymmetrical shadows (p < 0.001). Non-LC patients were more likely to exhibit symmetrical infiltrations. A small fraction of both groups experienced relapse or moving patterns of ICI-P. Conclusion: ICI-P patients more often experienced other irAE prior to the development of ICI-P. The characteristics of ICI-P can differ in terms of the onset, KL-6 reliability, and chest CT findings between LC and non-LC patients. Advances in knowledge: In ICI-P patients, a history of other irAE can be more frequently observed. Differences in disease onset and radiological patterns between LC and non-LC patients might be helpful to make a diagnosis of ICI-P; however, longitudinal observation of chest CT scans is advised to observe the pneumonitis activity irrespective of cancer types.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors
    Chu, Xiangling
    Zhao, Jing
    Zhou, Juan
    Zhou, Fei
    Jiang, Tao
    Jiang, Sen
    Sun, Xiwen
    You, Xiaofang
    Fengying, Fengying
    Ren, Shengxiang
    Zhou, Caicun
    Su, Chunxia
    LUNG CANCER, 2020, 150 : 76 - 82
  • [42] The Risk Factors Associated with Immune Checkpoint Inhibitor-Related Pneumonitis
    Asada, Mizuho
    Mikami, Takahisa
    Niimura, Takahiro
    Zamami, Yoshito
    Uesawa, Yoshihiro
    Chuma, Masayuki
    Ishizawa, Keisuke
    ONCOLOGY, 2021, 99 (04) : 256 - 259
  • [43] Expansion of inflammatory macrophages in immune checkpoint inhibitor-related pneumonitis
    Cui, Xiaoran
    Hu, Yi
    Liu, Tianyi
    Zhi, Renyong
    Wu, Liangliang
    Yu, Yanju
    Li, Tao
    CANCER SCIENCE, 2025, 116 : 1154 - 1154
  • [44] CLINICAL AND PATHOLOGICAL FEATURES OF IMMUNE CHECKPOINT INHIBITOR-RELATED LIVER INJURY
    Sunago, Kotaro
    HEPATOLOGY, 2022, 76 : S589 - S590
  • [45] Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity
    Escudier, Marion
    Cautela, Jennifer
    Malissen, Nausicaa
    Ancedy, Yann
    Orabona, Morgane
    Pinto, Johan
    Monestier, Sandrine
    Grob, Jean-Jacques
    Scemama, Ugo
    Jacquier, Alexis
    Lalevee, Nathalie
    Barraud, Jeremie
    Peyrol, Michael
    Laine, Marc
    Bonello, Laurent
    Paganelli, Franck
    Cohen, Ariel
    Barlesi, Fabrice
    Ederhy, Stephane
    Thuny, Franck
    CIRCULATION, 2017, 136 (21) : 2085 - 2087
  • [46] Subsequent systemic therapy for non-small cell lung cancer patients with immune checkpoint inhibitor-related interstitial lung disease
    Sato, Yusuke
    Watanabe, Satoshi
    Ota, Takeshi
    Kushiro, Kohei
    Fujisaki, Toshiya
    Takahashi, Miho
    Ohtsubo, Aya
    Shoji, Satoshi
    Nozaki, Koichiro
    Ichikawa, Kosuke
    Hokari, Satoshi
    Kondo, Rie
    Hayashi, Masachika
    Ishikawa, Hiroyuki
    Miyabayashi, Takao
    Abe, Tetsuya
    Miura, Satoru
    Tanaka, Hiroshi
    Okajima, Masaaki
    Terada, Masaki
    Ishida, Takashi
    Iwashima, Akira
    Sato, Kazuhiro
    Yoshizawa, Hirohisa
    Aoki, Nobumasa
    Ohshima, Yasuyoshi
    Koya, Toshiyuki
    Kikuchi, Toshiaki
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (07) : 3132 - +
  • [47] A nomogram model for predicting the risk of checkpoint inhibitor-related pneumonitis for patients with advanced non-small-cell lung cancer
    Zhang, Yao
    Zhang, Lincheng
    Cao, Shuhui
    Wang, Yue
    Ling, Xuxinyi
    Zhou, Yan
    Zhong, Hua
    CANCER MEDICINE, 2023, 12 (15): : 15998 - 16010
  • [48] Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting
    Moey, Melissa Y. Y.
    Tomdio, Anna N.
    McCallen, Justin D.
    Vaughan, Lauren M.
    O'Brien, Kevin
    Naqash, Abdul R.
    Cherry, Cynthia
    Walker, Paul R.
    Carabello, Blase A.
    JACC: CARDIOONCOLOGY, 2020, 2 (03): : 491 - 502
  • [49] A Case of Lung Cancer with Very-Late-Onset Immune Checkpoint Inhibitor-Related Myocarditis
    Nishikawa, Tatsuya
    Tamiya, Motohiro
    Ohta-Ogo, Keiko
    Ikeda, Yoshihiko
    Hatakeyama, Kinta
    Honma, Keiichiro
    Yasui, Taku
    Shioyama, Wataru
    Oka, Toru
    Inoue, Takako
    Kumagai, Toru
    Fujita, Masashi
    CJC OPEN, 2022, 4 (07) : 651 - 655
  • [50] Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer
    Lin, Xinqing
    Deng, Haiyi
    Yang, Yilin
    Wu, Jianhui
    Qiu, Guihuan
    Li, Suyang
    Xie, Xiaohong
    Liu, Ming
    Xie, Zhanhong
    Qin, Yinyin
    Song, Yong
    Zhou, Chengzhi
    FRONTIERS IN ONCOLOGY, 2021, 11